Carfilzomib demonstrates broad anti-tumor activity in pre-clinical non-small cell and small cell lung cancer models

Table 2 Inhibitory activity of CFZ combined with CDDP in lung cancer cell lines

Cell line	Simultaneous		CDDP→CFZ		CDDP→CFZ
Cell line	IC₅₀(nM)	Synergy Value	IC₅₀(nM)	Synergy Value	IC₅₀(nM)	Synergy Value
NSCLC
H520	14.5	Ant.	427.3	Ant. +	87.6	Ant. +
A549	<1	NC	206.2	Ant. +	72.3	Ant. +
H1993	173.1	Ant. +	134.0	Ant. +	200.6	Ant. +
H460	14.8	Syn.	258.3	Ant. +	25.1	Syn.
H1299	<1	NC	<1	NC	<1	NC
SCLC
SHP77	72.8	Syn.	171.8	Syn.	21.7	Syn. +
DMS114	<1	NC	<1	NC	<1	NC

Cells were treated with equivalent doses of CFZ and CDDP either simultaneously, CDDP followed by CFZ, or CFZ followed by CDDP and evaluated 96 hours after initial treatment. IC₅₀ values represent the concentration at which the drug combination inhibited cell growth by 50%. Synergy values were determined with Calcusyn software from the combination index (CI) method described by Chou and Talalay [31]. CI interpretation: <0.3 strong synergism (Syn. +), 0.3-0.9 synergism (Syn.), 1–3 antagonism (Ant.), >3 strong antagonism (Ant. +), or not calculated due to high cell death at lowest dose (NC).

ISSN: 1756-9966